2394: 18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry

Paula V. Estrada-Alarcón¹, Marta Domínguez², Rafael Benito Melero-Gonzalez³, Eugenio De Miguel⁴, Maria. T Silva-Diaz⁵, Jesús Alejandro Valero⁶, Ismael González⁷, Julio Sanchez Martin⁸, Javier Narvaez⁹, Eva Galindez-Agirregoikoa¹⁰, javier Mendizábal¹¹, lydia Abasolo¹², Javier Loricera⁸, Alejandro Muñoz¹³, Santos Castañeda¹⁴, Patricia Moya¹⁵, patricia Moran Alvarez¹⁶, Vanesa Navarro¹⁷, Carles Galisteo¹⁸, Ivette Casafont-Solé¹⁹, Jose Andres Roman Ivorra²⁰, TAREK CARLOS SALMAN MONTE²¹, Margarida Rocha²², Carlota Laura Iñiguez²³, Alicia García²⁴, Cristina Campos²⁵, María Alcalde²⁶, Antonio Juan Mas²⁷, Francisco Javier Prado²⁸, Ricardo Blanco²⁹ and On Behalf of ARTESER Working Group³⁰, ¹Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Vigo, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Department of Rheumatology, Hospital Universitario Donostia, San Sebastián, Spain, ⁷Hospital Universitario de León, León, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Basurto University Hospital, Bilbao, Spain, ¹¹Complejo Hospitalario de Navarra, Pamplona, Spain, ¹²Hospital Clínico San Carlos, Madrid, Spain, ¹³Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁶Hospital Ramón y Cajal, Madrid, Spain, ¹⁷H Moisès Broggi, Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitario Parc Taulí, Sabadell, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitari i Politècnic la Fe, Valencia, Spain, ²¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²²Osakidetza, Bilbo, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Hospital Universitario de Canarias, Islas Canarias, ²⁵Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ²⁶Hospital Severo Ochoa, Madrid, Spain, ²⁷Hospital Universitario Son Llàtzer, Mallorca, Spain, ²⁸Research department Hospital Infantil de México Federico Gómez, Mexico City, Mexico, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁰SER, Spain

Background/Purpose: Imaging studies in patients with giant cell arteritis (GCA) and suspected large vessel vasculitis (LVV) are sensitive, increasingly available, and less aggressive than temporal artery biopsy. Positron emission tomography/computed tomography (PET/CT) with 18-fluorodeoxyglucose (18F-FDG) allows for the evaluation of mural inflammation in extracranial arteries and supports the diagnosis of LVV. This study aimed to analyze in which patients with GCA the use of 18F-FDG-PET/CT is useful for detecting LVV.

Methods: ARTESER is a large Spanish registry promoted by the Spanish Society of Rheumatology, including patients with a new diagnosis of GCA, from June 2013 to March 2019. A selection of patients who underwent an 18F-FDG-PET/CT was carried out. The main variable of the study was the presence of vasculitis detected by this imaging technique. The diagnosis of LVV was based on expert opinion. Demographic variables, comorbidities, acute phase reactants, cumulative dose of glucocorticoids prior to the test, and the number of days elapsed before performing the test were considered. The clinical phenotypes were defined as cranial or extracranial, depending on the main symptom at the moment of diagnosis. Results are presented as a bivariable model to analyze differences between patients with positive and negative results, a regression model to approach the association between variables in those with a positive test, and a ROC area under the curve analysis.

Results: From a total of 1675 GCA patients, included in ARTESER registry, 377 met the inclusion criteria of having an 18F-FDG-PET/CT done during the diagnostic process. Table 1 shows the bivariable analysis. 67.4% of patients presented as a cranial-GCA phenotype and 29.1% as extracranial-GCA variant, 18 patients could not be classified as either phenotype. Sixty-five percent of patients in our registry had LVV, as detected by 18F-FDG-PET/CT (n=245). In those patients with a positive PET/TC, the vascular territory most frequently affected was the thoracic aorta (85.7%), followed by supra-aortic vessels (78.8%), and abdominal aorta (57.6%). Cardiovascular risk factors were more frequent in patients with a negative 18F-FDG-PET/CT (Table 1). The regression model (Table 2) shows a negative association with a positive 18F-FDG-PET/CT for older patients, patients with diabetes mellitus and cardiovascular disease and, the odds ratio for having a positive 18F-FDG-PET/TC is lower, as days go by. No variables were found to have a positive association with a positive 18F-FDG-PET/TC. Depending on the cumulative dosage of glucocorticoids, 18F-FDG-PET/CT had an area under the curve of 0.74 (Figure 1).

Conclusion: Younger patients have a higher probability of presenting a LVV detected by 18F-FDG-PET/CT. Patients with cardiovascular risk factors (hypertension, diabetes mellitus, smoking), have a higher probability of a negative 18F-FDG-PET/CT. The most frequent large vessel affected was the thoracic aorta. As days go off, and the cumulative glucocorticoid dose is higher, vascular wall uptake of 18F-FDG is reduced, the reason why 18F-FDG-PET/CT should be performed as soon as possible.








P. Estrada-Alarcón: None; M. Domínguez: None; R. Melero-Gonzalez: None; E. De Miguel: None; M. Silva-Diaz: None; J. Valero: None; I. González: None; J. Sanchez Martin: None; J. Narvaez: None; E. Galindez-Agirregoikoa: None; j. Mendizábal: None; l. Abasolo: None; J. Loricera: None; A. Muñoz: None; S. Castañeda: None; P. Moya: None; p. Moran Alvarez: None; V. Navarro: None; C. Galisteo: None; I. Casafont-Solé: None; J. Roman Ivorra: None; T. SALMAN MONTE: None; M. Rocha: None; C. Iñiguez: None; A. García: None; C. Campos: None; M. Alcalde: None; A. Mas: None; F. Prado: None; R. Blanco: AbbVie, 5, 6, Amgen, 6, AstraZeneca, 2, BMS, 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6; O. ARTESER Working Group: None.